TORONTO — Metro is heading into 2025 with renewed capacity to grow its business after reaching the final milestone in its ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its attendance at the 43rd Annual J.P. Morgan Healthcare ...

Unlike previous models, which required converting images and audio into text before analysis, Gemini 2.0 processes them. The ...

Frost & Sullivan researched the bioinformatics-based drug discovery and development industry, and based on its analysis results, today recognized DNAnexus, provider of the leading enterprise platform ...